Vision Scientists Discover New Eye Treatment for Seasonal Allergies
24-Apr-2018 2:05 PM EDT
Newswise — Honolulu, Hawaii – A recent study shows that a new eye drop may be a potentially effective treatment for seasonal eye allergies, a condition affecting millions of people worldwide. The findings will be presented at the 2018 Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO) in Honolulu, Hawaii, Sunday, April 29 – Thursday, May 3.
In a set of studies, the scientists assessed whether or not a non-antihistamine drug that targets a specific gene linked to eye infections could be a potential option to treat patients suffering from seasonal allergies. The team evaluated different biological fluids before administering the compound in eye drop form to a mouse model with eye allergies.
Results showed that this treatment for pollen-induced eye allergies reduced allergy-related symptoms (swelling and tearing) by 50 – 80%. According to the researchers, these observations were equivalent to those observed in response to Patanol and Levocabastine — two frequently prescribed antihistamine eye drop medications used to treat seasonal eye allergies.
“This new therapy allows the number of administrations to be reduced to once daily without inducing systemic side effects, and it is expected to improve the quality of life for patients suffering from seasonal allergies,” says Victoria Gonzalez Mpharm, PhD, of Sylentis, a Spain-based company that specializes in development of ocular treatments based in RNA interference.
Abstract title: Development of a RNAi therapeutic for the treatment of allergic conjunctivitis
Presentation start/end time: Tuesday, May 1, 8:15 – 10am
Location: Kamehameha Exhibit Hall Abstract number: 5567 - A0259
The Association for Research in Vision and Ophthalmology (ARVO) is the largest eye and vision research organization in the world. Members include nearly 11,000 eye and vision researchers from over 75 countries. ARVO advances research worldwide into understanding the visual system and preventing, treating and curing its disorders.
All abstracts accepted for presentation at the ARVO Annual Meeting represent previously unpublished data and conclusions. This research may be proprietary or may have been submitted for journal publication. Embargo policy: Journalists must seek approval from the presenter(s) before reporting data from paper or poster presentations. Press releases or stories on information presented at the ARVO Annual Meeting may not be released or published until the conclusion of the presentation.